α-Phenylglycid-saeure | 64918-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: α-Phenylglycid-saeure
• 英文别名: 2-phenyl-oxiranecarboxylic acid；2-Phenyloxirane-2-carboxylic acid
• CAS: 64918-95-2
• 化学式: C₉H₈O₃
• 分子量: 164.161
• InChiKey: KJOJTPANXQIYQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  α-Phenylglycid-saeure 、 氯甲酸乙酯 、 三乙胺 生成 ethoxycarbonyl 2-phenyloxirane-2-carboxylate
  参考文献：
  名称：

  THUS L.; SMEETS F. L. M.; CILLISSEN P. J. M.; HARMSEN J.; ZWANENBURG B., TETRAHEDRON, 1980, 36, NO 14, 2141-2143

  摘要：

  DOI：
• 作为产物：
  描述：

  sodium a-phenylglycidate 、 盐酸 生成 α-Phenylglycid-saeure
  参考文献：
  名称：

  THUS L.; SMEETS F. L. M.; CILLISSEN P. J. M.; HARMSEN J.; ZWANENBURG B., TETRAHEDRON, 1980, 36, NO 14, 2141-2143

  摘要：

  DOI：

文献信息

• [EN] METHOD FOR THE MANUFACTURE OF COMPOUNDS CONTAINING AN a-OXY PHOSPHORUS GROUP<br/>[FR] PROCÉDÉ POUR LA FABRICATION DE COMPOSÉS CONTENANT UN GROUPE ?-OXY-PHOSPHORÉ
  申请人：STRAITMARK HOLDING AG

  公开号：WO2012098255A1

  公开（公告）日：2012-07-26

  A method for the manufacture of compounds containing an α-oxy phosphorus group is disclosed. A P-O component having at least one P-O-P moiety, whereby at least one phosphorus has the +3 oxidation state, is added in specific proportions to a compound containing an α-oxy carboxylic acid group, followed by conducting the reaction and adding water subsequently. The compounds containing an α-oxy phosphorus group formed can then be recovered.

  披露了一种含有α-氧磷基团的化合物的制造方法。将至少含有一个P-O-P基团的P-O组分，其中至少一个磷处于+3氧化态，按特定比例添加到含有α-氧羧酸基团的化合物中，然后进行反应并在随后加入水。随后可以回收形成的含有α-氧磷基团的化合物。
• Method for the preparation of aryl ethers
  申请人：Cebula Mateusz

  公开号：US20050187388A1

  公开（公告）日：2005-08-25

  The invention provides a method of preparing a compound of formula (I): wherein R, R 1 , n and m are as defined herein, or a pharmaceutically acceptable salt thereof.

  该发明提供了一种制备式(I)化合物的方法：其中R、R1、n和m如本文所定义，或其药用可接受的盐。
• Process for preparing 1,5-benzothiazepin derivatives
  申请人：DSM N.V.

  公开号：EP0450705A1

  公开（公告）日：1991-10-09

  The invention relates to a process for preparing a preferably stereoisomerically pure 1,5-benzothiazepin derivative with the general formula (I) by the cyclization of an ester of the corresponding 2-hydroxy-3-(4-R₃-phenyl)--3-(2-aminoarylthio)propanoic acid with the general formula (II) in the presence of a base and in an aprotic, polar solvent where R₁ and R₂, each independently, represent hydrogen, halogen, or an alkyl group with 1-6 carbon atoms or together with the phenyl group to which they are attached from a naphtalene group, R₄ represents a residual group with 1-20 carbon atoms and R₃ a hydrogen atom, a hydroxy group or an alkoxy group with 1-6 carbon atoms, at which a 2-hydroxy-3-(4-R₃-phenyl)-3-(2-aminoarylthio)propanoic acid ester with the general formula (II) is cyclized in the presence of an alkali metal alkanolate as base. The invention also relates to a process for the preparation of alkylated and/or acylated 1,5-benzothiazepin derivatives and to the new compounds of (2X,3Y)-2-phenyl-3-hydroxy-2,3-dihydro-1,5-benzothiazepin-4(5H)-one, (2X,3Y)-2-phenyl-3-hydroxy-5-[2-(dimethylamino)ethyl]-2,3-di hydro-1,5-benzothiazepin-4(5H)-one and (2X,3Y)-2-phenyl--3-acetyloxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-1,5-benz othiazepin-4(5H)-one, where X and Y each independently represent the R or S configuration. Application of 1,5-benzothiazepin derivatives, obtained according to the process of the present invention, in the preparation of pharmaceuticals and particularly in the preparation of diltiazem.

  该发明涉及一种制备偏好立体异构纯的1,5-苯并噻吩基衍生物的过程，其具有通式（I），通过在无水极性溶剂中，在碱的存在下，将相应的2-羟基-3-(4-R₃-苯基)-3-(2-氨基芳硫基)丙酸酯与通式（II）进行环化，其中R₁和R₂，各自独立地代表氢、卤素或具有1-6个碳原子的烷基基团，或与它们连接的苯基一起形成萘基，R₄代表具有1-20个碳原子的残基，R₃代表氢原子、羟基或具有1-6个碳原子的烷氧基，在碱金属烷醇盐存在下，通过环化2-羟基-3-(4-R₃-苯基)-3-(2-氨基芳硫基)丙酸酯与通式（II）。 该发明还涉及一种制备烷基化和/或酰化1,5-苯并噻吩基衍生物的过程以及新化合物(2X,3Y)-2-苯基-3-羟基-2,3-二氢-1,5-苯并噻吩-4(5H)-酮，(2X,3Y)-2-苯基-3-羟基-5-[2-(二甲氨基)乙基]-2,3-二氢-1,5-苯并噻吩-4(5H)-酮和(2X,3Y)-2-苯基-3-乙酰氧基-5-[2-(二甲氨基)乙基]-2,3-二氢-1,5-苯并噻吩-4(5H)-酮，其中X和Y各自独立地代表R或S构型。 根据本发明的过程获得的1,5-苯并噻吩基衍生物的应用，特别是在制备药物，尤其是地尔硫卓的制备中。
• Stereoselective chemoenzymatic process for the preparation of optically enriched phenylglycidates as precursors of taxol side chain
  申请人：COUNCIL OF SCIENTIFIC AND INDUSTRIAL

  公开号：US20040259943A1

  公开（公告）日：2004-12-23

  The present invention relates to a novel and efficient chemoenzymatic process of preparation of optically active trans alkyl phenylglycidates. The invention particularly discloses a novel process for the chemoenzymatic synthesis of two enantiomers of trans alkyl phenylglycidate i.e. alkyl(2S,3R)-phenylglycidate and alkyl(2R,3S)-phenylglycidate of formulae 7 and 8 respectively. 1

  本发明涉及一种新颖有效的化学酶法制备光学活性反式烷基苯基乙二酸酯的方法。该发明特别揭示了一种新的化学酶法合成反式烷基苯基乙二酸酯的两个对映异构体，即式7和式8的烷基(2S,3R)-苯基乙二酸酯和烷基(2R,3S)-苯基乙二酸酯。
• Cephalotaxane derivatives and their processes of preparation and purification
  申请人：Robin Jean-Pierre

  公开号：US20050090484A1

  公开（公告）日：2005-04-28

  The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.

  本发明涉及一种新的不对称半合成哈林顿碱及其类似物的通用工艺，这些碱是用于化疗的生物碱。该工艺包括将天然的头孢松与一个酰化化合物直接酯化，该化合物由一个侧链前体构成，其主干和功能化已经完全形成。该发明还涉及以下式子的天然、合成或半合成哈林顿碱及其互变异构体和盐：其中n=2（即哈林顿碱）或n=3（即同型哈林顿碱），其中可能包括对映异构体在内的总杂质含量低于1％，和/或主要杂质含量低于0.9％，和/或色谱测定显示哈林顿碱含量高于97.5％。